IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 8, 2016, Pages 1530-1548

  Kelchtermans, H ^a,b   Pelkmans, L ^a,b   de Laat, B ^a,b   Devreese, K M ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Synapse BV   (Netherlands)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

anti cardiolipin; anti phospholipid antibody; antiphospholipid syndrome; IgM; 2 glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; COMPUTER ANALYSIS; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS;

EID: 84983345694     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13379     Document Type: Article

References (195)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
2. Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 399–401.
3. Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1048–9.
4. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–32.
5. Tuhrim S, Rand JH, Wu XX, Weinberger J, Horowitz DR, Goldman ME, Godbold JH. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999; 30: 1561–5.
6. Devreese KM. Antiphospholipid antibodies: evaluation of the thrombotic risk. Thromb Res 2012; 130(Suppl. 1): S37–40.
7. Devreese KM. Antiphospholipid antibody testing and standardization. Int J Lab Hematol 2014; 36: 352–63.
8. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 792–5.
9. Devreese KM. Standardization of antiphospholipid antibody assays. Where do we stand? Lupus 2012; 21: 718–21.
10. Adamczuk YP, Iglesias Varela ML, Martinuzzo ME, Cerrato GS, Forastiero RR. Central retinal vein occlusion and thrombophilia risk factors. Blood Coagul Fibrinolysis 2002; 13: 623–6.
11. Adler S, Szczech L, Qureshi A, Bollu R, Thomas-John R. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 2001; 56: 428–34.
12. Aguirre V, Cuchacovich R, Barria L, Aris H, Trejo C, Massardo L, Pasten R, Espinoza L. Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE). Lupus 2001; 10: 75–80.
13. Ahluwalia J, Singh S, Garewal G. Antiphospholipid antibodies in children with systemic lupus erythematosus: a prospective study in northern India. Rheumatol Int 2005; 25: 530–5.
14. Ahluwalia J, Singh S, Naseem S, Suri D, Rawat A, Gupta A, Masih J, Bose S. Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India. Rheumatol Int 2014; 34: 669–73.
15. Ahmadi AR, Joshaghani HR, Mansourian AR, Salehi A, Behnampour N. The comparison of acute myocardial infarction serum anticardiolipin antibody with healthy subjects, in Gorgan (Northern Iran). Pak J Biol Sci 2013; 16: 92–6.
16. Alagozlu H, Bakici Z, Gultekin F, Yildirim B, Sezer H. Anticardiolipin antibody positivity in diabetic patients with and without diabetic foot. J Diabetes Complications 2002; 16: 172–5.
17. Amoroso A, Mitterhofer AP, Del Porto F, Garzia P, Ferri GM, Galluzzo S, Vadacca M, Caccavo D, Afeltra A. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003; 64: 265–73.
18. Andreoli L, Piantoni S, Dall'Ara F, Allegri F, Meroni PL, Tincani A. Vitamin D and antiphospholipid syndrome. Lupus 2012; 21: 736–40.
19. Ao W, Zheng H, Chen XW, Shen Y, Yang CD. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int 2011; 31: 865–9.
20. Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S, Berkun Y, Sztajnbok FR, Silva CA, Campos LM, Saad-Magalhaes C, Rigante D, Ravelli A, Martini A, Rozman B, Meroni PL. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008; 122: e1100–7.
21. Balada E, Ordi-Ros J, Paredes F, Villarreal J, Mauri M, Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 235–41.
22. Bank I, Tick LW, Hutten BA, Kramer MH, Middeldorp S, Buller HR. Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis. Pathophysiol Haemost Thromb 2003; 33: 192–6.
23. Bashshur ZF, Taher A, Masri AF, Najjar D, Arayssi TK, Noureddin BN. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. Retina 2003; 23: 486–90.
24. Becarevic M, Andrejevic S, Miljic P, Bonaci-Nikolic B, Majkic-Singh N. Serum lipids and anti-oxidized LDL antibodies in primary antiphospholipid syndrome. Clin Exp Rheumatol 2007; 25: 361–6.
25. Becker AC, Jacobson B, Singh S, Sliwa K, Stewart S, Libhaber E, Essop MR. The thrombotic profile of treatment-naive HIV-positive Black South Africans with acute coronary syndromes. Clin Appl Thromb Hemost 2011; 17: 264–72.
26. Bergrem A, Jacobsen EM, Skjeldestad FE, Jacobsen AF, Skogstad M, Sandset PM. The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis – a population-based case–control study. Thromb Res 2010; 125: e222–7.
27. Berman H, Rodriguez-Pinto I, Cervera R, Gregory S, de Meis E, Rodrigues CE, Aikawa NE, de Carvalho JF, Springer J, Niedzwiecki M, Espinosa G; Catastrophic Registry Project Group. Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the ‘CAPS Registry’. Autoimmun Rev 2014; 13: 157–62.
28. Bertolaccini ML, Gomez S, Pareja JF, Theodoridou A, Sanna G, Hughes GR, Khamashta MA. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64: 1639–43.
29. Bidot CJ, Jy W, Horstman LL, Huisheng H, Jimenez JJ, Yaniz M, Ahn YS. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003; 120: 618–26.
30. Bizzaro N, Ghirardello A, Zampieri S, Iaccarino L, Tozzoli R, Ruffatti A, Villalta D, Tonutti E, Doria A. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007; 5: 1158–64.
31. Blohorn A, Guegan-Massardier E, Triquenot A, Onnient Y, Tron F, Borg JY, Mihout B. Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: a descriptive study of 139 patients. Cerebrovasc Dis 2002; 13: 156–62.
32. Bonduel M, Hepner M, Sciuccati G, Torres AF, Tenembaum S. Prothrombotic disorders in children with moyamoya syndrome. Stroke 2001; 32: 1786–92.
33. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001; 32: 1701–6.
34. Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104: 143–8.
35. Caldas CA, de Carvalho JF. Primary antiphospholipid syndrome with and without Sneddon's syndrome. Rheumatol Int 2011; 31: 197–200.
36. Calvo-Romero JM. Anticardiolipin antibodies in patients with venous thromboembolic disease from a Spanish rural area. Clin Appl Thromb Hemost 2009; 15: 247–8.
37. Camargo EW, Freire PV, Silva CA, dos Santos NR, da Mota LM, Pereira RM, de Carvalho JF. Antiphospholipid syndrome plus rheumatic fever: a higher risk factor for stroke? Rheumatol Int 2012; 32: 1721–5.
38. Canaud G, Bienaime F, Noel LH, Royal V, Alyanakian MA, Dautzenberg MD, Rabant M, Posson J, Thervet E, Anglicheau D, Kreis H, Martinez F, Legendre C, Zuber J. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010; 10: 2051–60.
39. Caramaschi P, Poli G, Bonora A, Volpe A, Tinazzi I, Pieropan S, Bambara LM, Biasi D. A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine 2010; 77: 330–4.
40. Carbone J, Sanchez-Ramon S, Cobo-Soriano R, Seoane E, Aparicio MJ, Ruiz-Tiscar JL, Rodriguez-Mahou M, Rodriguez-Molina JJ, Sarmiento E, Cortes C, Fernandez-Cruz E. Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with ocular inflammatory diseases. J Rheumatol 2001; 28: 2437–41.
41. Castellino G, Cuadrado MJ, Godfrey T, Khamashta MA, Hughes GR. Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. Ann Rheum Dis 2001; 60: 527–30.
42. Coloma Bazan E, Donate Lopez C, Moreno Lozano P, Cervera R, Espinosa G. Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol Res 2013; 56: 358–61.
43. Damoiseaux J, Peeters L, Hupperts R, Boreas A, ten Cate H, Tervaert JW. Prevalence of anticardiolipin antibodies in patient cohorts with distinct clinical manifestations of the antiphospholipid syndrome. Ann N Y Acad Sci 2009; 1173: 146–51.
44. Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36: 1195–9.
45. de Carvalho JF. Influence of gender on the clinical and laboratory spectra of patients with primary antiphospholipid syndrome. Rheumatol Int 2011; 31: 647–50.
46. de Godoy JM, Batigalia F, Braile DM. Superficial thrombophlebitis and anticardiolipin antibodies – report of association. Angiology 2001; 52: 127–9.
47. de Godoy JM, de Godoy MF, Braile DM. Recurrent thrombosis in patients with deep vein thrombosis and/or venous thromboembolism associated with anticardiolipin antibodies. Angiology 2006; 57: 79–83.
48. de Laat B, Derksen RH, Mackie IJ, Roest M, Schoormans S, Woodhams BJ, de Groot PG, van Heerde WL. Annexin A5 polymorphism (−1C–>T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 1468–72.
49. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109: 1490–4.
50. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598–602.
51. de Meis E, Monteiro RQ, Levy RA. Lung adenocarcinoma and antiphospholipid antibodies. Autoimmun Rev 2009; 8: 529–32.
52. de Souza AW, Silva NP, de Carvalho JF, D'Almeida V, Noguti MA, Sato EI. Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus 2007; 16: 782–7.
53. Deeb A, Hamdoun S, Dababo K. Prevalence of antiphospholipid antibodies in Syrian patients with thrombosis. Iran J Immunol 2009; 6: 154–9.
54. Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, Veit V, Combes V, Gentile S, Moal V, Sanmarco M, Sampol J. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91: 667–73.
55. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalcaci M, Inanc M. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760–4.
56. Diz-Kucukkaya R, Hancer VS, Inanc M, Nalcaci M, Pekcelen Y. Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. Lupus 2004; 13: 32–5.
57. Diz-Kucukkaya R, Inanc M, Afshar-Kharghan V, Zhang QE, Lopez JA, Pekcelen Y. P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome. Ann Rheum Dis 2007; 66: 1378–80.
58. Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Radovanovic S, Marisavljevic D. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J 2014; 16: 162–7.
59. Donohoe S, MacKie IJ, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001; 113: 544–9.
60. Dragoni F, Chiarotti F, Rosano G, Simioni P, Tormene D, Mazzucconi MG, Cafolla A, Avvisati G. Thrombophilic screening in young patients (< 40 years) with idiopathic ischemic stroke: a controlled study. Thromb Res 2011; 127: 85–90.
61. Echigo T, Hasegawa M, Inaoki M, Yamazaki M, Sato S, Takehara K. Antiphospholipid antibodies in patients with autoimmune blistering disease. J Am Acad Dermatol 2007; 57: 397–400.
62. Falcao CA, Alves IC, Chahade WH, Duarte AL, Lucena-Silva N. Echocardiographic abnormalities and antiphospholipid antibodies in patients with systemic lupus erythematosus. Arq Bras Cardiol 2002; 79: 285–91.
63. Forastiero R, Martinuzzo M, Pombo G, Puente D, Rossi A, Celebrin L, Bonaccorso S, Aversa L. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231–8.
64. Furmanczyk-Zawiska A, Baczkowska T, Sadowska A, Szmidt J, Chmura A, Durlik M. Antiphospholipid antibodies in renal allograft recipients. Transplant Proc 2013; 45: 1655–60.
65. Furmanczyk-Zawiska A, Tronina O, Baczkowska T, Chmura A, Durlik M. The significance of antiphospholipid antibodies in liver recipients. Transplant Proc 2013; 45: 1983–9.
66. Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchioli R, Wisloff F, Marziali S, Morboeuf O, Barbui T. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110: 1178–83.
67. Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013; 22: 18–25.
68. Genvresse I, Luftner D, Spath-Schwalbe E, Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma. Eur J Haematol 2002; 68: 84–90.
69. Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560–7.
70. Glasnovic M, Bosnjak I, Vcev A, Soldo I, Bedekovic D, Milakovic S, Hecimovic V, Horvatic E, Bardek M. Vascular thrombosis associated with antiphospholipid syndrome. Coll Antropol 2008; 32: 103–7.
71. Gould T, Tikly M, Asherson R, Loizou S, Singh S. Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 29–34.
72. Grika EP, Ziakas PD, Zintzaras E, Moutsopoulos HM, Vlachoyiannopoulos PG. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012; 39: 516–23.
73. Gris JC, Bouvier S, Molinari N, Galanaud JP, Cochery-Nouvellon E, Mercier E, Fabbro-Peray P, Balducchi JP, Mares P, Quere I, Dauzat M. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119: 2624–32.
74. Gultekin F, Alagozlu H, Candan F, Nadir I, Bakici MZ, Sezer H. The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis. ASAIO J 2005; 51: 162–4.
75. Hadhri S, Rejeb MB, Belarbia A, Achour A, Skouri H. Hemodialysis duration, human platelet antigen HPA-3 and IgA isotype of anti-beta2glycoprotein I antibodies are associated with native arteriovenous fistula failure in Tunisian hemodialysis patients. Thromb Res 2013; 131: e202–9.
76. Haga HJ, Jacobsen EM, Peen E. Incidence of thromboembolic events in patients with primary Sjogren's syndrome. Scand J Rheumatol 2008; 37: 127–9.
77. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost 2002; 87: 802–7.
78. Hendler MF, Meschengieser SS, Blanco AN, Alberto MF, Salviu MJ, Gennari L, Lazzari MA. Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects. Am J Hematol 2004; 76: 330–7.
79. Hernandez-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol 2013; 31: 382–8.
80. Hirmerova J, Ulcova-Gallova Z, Seidlerova J, Filipovsky J, Bibkova K, Micanova Z, Mayer O Jr. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost 2010; 16: 318–25.
81. Hodak E, Feuerman H, Molad Y, Monselise Y, David M. Primary anetoderma: a cutaneous sign of antiphospholipid antibodies. Lupus 2003; 12: 564–8.
82. Hsieh K, Knobl P, Rintelen C, Kyrle PA, Quehenberger P, Bialonczyk C, Partsch H, Lechner K, Pabinger I. Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome? Br J Haematol 2003; 123: 490–5.
83. Huang Z, Jacewicz M, Pfeiffer RF. Anticardiolipin antibody in vascular parkinsonism. Mov Disord 2002; 17: 992–7.
84. Hudson M, Herr AL, Rauch J, Neville C, Chang E, Ibrahim R, Seguin C, Kassis J, Busque L, Fortin PR. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 2003; 30: 2385–91.
85. Ilhan F, Celiker U, Godekmerdan A, Kan E. The antiphospholipid antibody syndrome research in patients with retinal venous occlusion. Arch Med Res 2005; 36: 372–5.
86. Immanuel S, Giantini A, Dharma RS; Samino. The role of persistent anticardiolipin antibody as risk factor of ischemic stroke. Acta Med Indones 2005; 37: 205–9.
87. Ishikura K, Wada H, Kamikura Y, Hattori K, Fukuzawa T, Yamada N, Nakamura M, Nobori T, Nakano T. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. Am J Hematol 2004; 76: 338–42.
88. Jy W, Tiede M, Bidot CJ, Horstman LL, Jimenez JJ, Chirinos J, Ahn YS. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 2007; 121: 319–25.
89. Kahles T, Humpich M, Steinmetz H, Sitzer M, Lindhoff-Last E. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke. Rheumatology (Oxford) 2005; 44: 1161–5.
90. Kahwa EK, Sargeant LA, McFarlane-Anderson N, Smikle MF, Forrester T, Wilks RJ. Anticardiolipin antibodies and risk of thromboembolic disease in young Jamaican women. J Cardiovasc Risk 2001; 8: 349–54.
91. Kim H, Kim JE, Hwang SM, Lee HR, Han KS, Kim HK. Synergistic thrombotic risk of antibodies against phosphatidylserine and prothrombin and beta-2-glycoprotein I. Clin Appl Thromb Hemost 2014; 20: 442–7.
92. Koskenmies S, Vaarala O, Widen E, Kere J, Palosuo T, Julkunen H. The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus. Scand J Rheumatol 2004; 33: 246–52.
93. Lee SS, Cho ML, Joo YS, Kim WU, Hong YS, Min JK, Lee SH, Park SH, Cho CS, Kim HY. Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 520–4.
94. Lenicek Krleza J, Ethuranovic V, Bronic A, Coen Herak D, Mejaski-Bosnjak V, Zadro R. Multiple presence of prothrombotic risk factors in Croatian children with arterial ischemic stroke and transient ischemic attack. Croat Med J 2013; 54: 346–54.
95. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine C, Levin B, Triplett DA, Mohr JP; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576–84.
96. Liberati AP, Ribeiro CF, Skare T. Study about the association between anticardiolipin antibodies and peripheral vascular phenomena in patients suffering from systemic scleroderma. An Bras Dermatol 2010; 85: 403–5.
97. Lien LM, Chen WH, Chiu HC, Pan WH, Chen JR, Bai CH. High titer of anticardiolipin antibody is associated with first-ever ischemic stroke in Taiwan. Cerebrovasc Dis 2006; 22: 225–30.
98. Lindhoff-Last E, Humpich M, Schmitt J, Rodiger S, Seifried E, Bauersachs R. MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant. Clin Appl Thromb Hemost 2002; 8: 163–7.
99. Locht H, Wiik A. IgG and IgM isotypes of anti-cardiolipin and anti-beta2-glycoprotein I antibodies reflect different forms of recent thrombo-embolic events. Clin Rheumatol 2006; 25: 246–50.
100. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004; 121: 142–9.
101. Lopez-Pedrera C, Aguirre MA, Buendia P, Barbarroja N, Ruiz-Limon P, Collantes-Estevez E, Velasco F, Khamashta M, Cuadrado MJ. Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum 2010; 62: 869–77.
102. Maaroufi RM, Hamdi R, Jmili N, Ghorbal M, Hamida BH, Mahjoub T. Antiphospholipid syndrome and retinal vein occlusion in adults. East Mediterr Health J 2004; 10: 627–32.
103. Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, Mitchell L. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106: 4152–8.
104. Margarido PF, D'Amico E, Bagnoli VR, Fonseca AM, Halbe HW, Pinotti JA. Thrombophilic profile of climacteric and menopausal women with venous thromboembolism. Climacteric 2002; 5: 87–9.
105. Martinez-Zamora MA, Peralta S, Creus M, Tassies D, Reverter JC, Espinosa G, Cervera R, Carmona F, Balasch J. Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case–control study. Ann Rheum Dis 2012; 71: 61–6.
106. Matyja-Bednarczyk A, Swadzba J, Iwaniec T, Sanak M, Dziedzina S, Cmiel A, Musial J. Risk factors for arterial thrombosis in antiphospholipid syndrome. Thromb Res 2014; 133: 173–6.
107. Medina G, Vera-Lastra O, Barile L, Salas M, Jara LJ. Clinical spectrum of males with primary antiphospholipid syndrome and systemic lupus erythematosus: a comparative study of 73 patients. Lupus 2004; 13: 11–16.
108. Mehrani T, Petri M. IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J Rheumatol 2011; 38: 450–3.
109. Mehta N, Uchino K, Fakhran S, Sattar MA, Branstetter BFt, Au K, Navratil JS, Paul B, Lee M, Gallagher KM, Manzi S, Ahearn JM, Kao AH. Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke 2008; 39: 3236–41.
110. Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, Tincani A. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 2007; 5: 2421–8.
111. Miesbach W, Gilzinger A, Gokpinar B, Claus D, Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosurg 2006; 108: 135–42.
112. Miesbach W, Matthias T, Scharrer I. Identification of thrombin antibodies in patients with antiphospholipid syndrome. Ann N Y Acad Sci 2005; 1050: 250–6.
113. Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 2006; 25: 840–4.
114. Mishra MN, Kalra R, Gupta MK. Antiphospholipid antibodies in young myocardial infarction patients. Indian J Biochem Biophys 2007; 44: 481–4.
115. Mishra MN, Rohatgi S. Antiphospholipid antibodies in young Indian patients with stroke. J Postgrad Med 2009; 55: 161–4.
116. Molino D, De Lucia D, Marotta R, Perna A, Lombardi C, Cirillo M, De Santo NG. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005; 68: 1223–9.
117. Musial J, Swadzba J, Motyl A, Iwaniec T. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J Rheumatol 2003; 30: 723–30.
118. Neville C, Rauch J, Kassis J, Chang ER, Joseph L, Le Comte M, Fortin PR. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003; 90: 108–15.
119. Niessner A, Graf S, Nikfardjam M, Speidl WS, Huber-Beckmann R, Zorn G, Wojta J, Huber K. Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease – a 13-year follow-up. Thromb Haemost 2003; 90: 344–50.
120. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, Kitani T, Iwatani Y, Kanakura Y. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001; 114: 647–54.
121. Ogunyemi D, Cuellar F, Ku W, Arkel Y. Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy. Am J Perinatol 2003; 20: 17–24.
122. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004; 351: 260–7.
123. Orzechowski NM, Wolanskyj AP, Ahlskog JE, Kumar N, Moder KG. Antiphospholipid antibody-associated chorea. J Rheumatol 2008; 35: 2165–70.
124. Owaidah TM, Qurashi FH, Al Nounou RM, Al Zahrani H, Al Mussa A, Tbakhi AI, Al Daama S, Elkum N, Roberts GT. Single center review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies. Hematology 2003; 8: 249–57.
125. De Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost 2010; 8: 1540–6.
126. Paccalin M, Manic H, Bouche G, Landron C, Mercie M, Boinot C, Gombert JM, Roblot P, Dighiero P. Antiphospholipid syndrome in patients with retinal venous occlusion. Thromb Res 2006; 117: 365–9.
127. Palomo I, Pereira J, Alarcon M, Vasquez M, Pinochet C, Velez MT, Sandoval J, Icaza G, Pierangeli S. Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis. Clin Rheumatol 2004; 23: 129–33.
128. Pelkmans L, Kelchtermans H, de Groot PG, Zuily S, Regnault V, Wahl D, Pengo V, de Laat B. Variability in exposure of epitope G40-R43 of domain I in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS ONE 2013; 8: e71402.
129. Pengo V, Denas G, Bison E, Banzato A, Jose SP, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, De Candia E, Montaruli B, Marietta M, Testa S, Barcellona D, Tripodi A; Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thromb Res 2010; 126: 150–3.
130. Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, Gouault M, Intrator L, Bierling P, Godeau B. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 2008; 142: 638–43.
131. Previtali S, Barbui T, Galli M. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study. Thromb Haemost 2002; 88: 729–32.
132. Proven A, Bartlett RP, Moder KG, Chang-Miller A, Cardel LK, Heit JA, Homburger HA, Petterson TM, Christianson TJ, Nichols WL. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc 2004; 79: 467–75.
133. Rabelo-Junior CN, Freire de Carvalho J, Lopes Gallinaro A, Bonfa E, Cocuzza M, Saito O, Silva CA. Primary antiphospholipid syndrome: morphofunctional penile abnormalities with normal sperm analysis. Lupus 2012; 21: 251–6.
134. Ramon I, Mathian A, Bachelot A, Hervier B, Haroche J, Boutin-Le Thi Huong D, Costedoat-Chalumeau N, Wechsler B, Karmali R, Velkeniers B, Touraine P, Coussieu C, Bennani A, Renard-Penna R, Grenier PA, Wahl D, Piette JC, Amoura Z. Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab 2013; 98: 3179–89.
135. Ranzolin A, Bohn JM, Norman GL, Manenti E, Bodanese LC, von Muhlen CA, Staub HL. Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol 2004; 83: 141–4; 137–40.
136. Robertson B, Urquhart C, Ford I, Townend J, Watson HG, Vickers MA, Greaves M. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007; 5: 1679–85.
137. Roggenbuck D, Egerer K, Feist E, Burmester GR, Dorner T. Antiphospholipid antibody profiling: association with the clinical phenotype of antiphospholipid syndrome? Comment on the article by Otomo et al. Arthritis Rheum 2012; 64: 2807–8; author reply 8–9.
138. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, Montecucco C, Rossi S, Caramaschi P, Biasi D, Doria A, Rampudda M, Monica N, Fischetti F, Picillo U, Brucato A, Salvan E, Vittorio P, Meroni P, Tincani A; Antiphospholipid Syndrome Study Group of the Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70: 1083–6.
139. Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M, Bertero MT, Bergia R, Caramaschi P, Biasi D, Capsoni F, Montaguti L, Ruffini R, Brucato A, Picillo U, Fanelli V, Riccieri V, Piccoli A, Valesini G, Doria A, Meroni PL, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 2009; 68: 397–9.
140. Ruiz-Garcia R, Serrano M, Martinez-Flores JA, Mora S, Morillas L, Martin-Mola MA, Morales JM, Paz-Artal E, Serrano A. Isolated IgA anti-beta2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J Immunol Res 2014; 2014: 704395.
141. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 1164–9.
142. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002; 119: 1005–10.
143. Sahin H, Aflay U, Kilinc N, Bircan MK. Coagulation parameters in the patients with Fournier's Gangrene. Int Urol Nephrol 2005; 37: 733–7.
144. Saidi S, Mahjoub T, Almawi WY. Lupus anticoagulants and anti-phospholipid antibodies as risk factors for a first episode of ischemic stroke. J Thromb Haemost 2009; 7: 1075–80.
145. Sailer T, Vormittag R, Koder S, Quehenberger P, Kaider A, Pabinger I. Clinical significance of anti-protein Z antibodies in patients with lupus anticoagulant. Thromb Res 2008; 122: 153–60.
146. Sailer T, Vormittag R, Pabinger I, Vukovich T, Lehr S, Quehenberger P, Panzer S, Lechner K, Zoghlami-Rintelen C. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol 2005; 32: 462–8.
147. Sailer T, Zoghlami C, Kurz C, Rumpold H, Quehenberger P, Panzer S, Pabinger I. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 2006; 95: 796–801.
148. Sairam S, Baethge BA, McNearney T. Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies. Clin Rheumatol 2003; 22: 24–9.
149. Samarkos M, Davies KA, Gordon C, Loizou S. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006; 25: 199–204.
150. Sanmarco M, Gayet S, Alessi MC, Audrain M, de Maistre E, Gris JC, de Groot PG, Hachulla E, Harle JR, Sie P, Boffa MC. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007; 97: 949–54.
151. Sebastian JK, Voetsch B, Stone JH, Romay-Penabad Z, Lo GH, Allen NB, Davis JC Jr, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Loscalzo J, Pierangeli S, Merkel PA; Wegener's Granulomatosis Etanercept Trial Research Group. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 2007; 34: 2446–50.
152. Seriolo B, Fasciolo D, Sulli A, Cutolo M. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol 2001; 19: 561–4.
153. Shen Y, Chen XW, Sun CY, Dai M, Yan YC, Yang CD. Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus 2010; 19: 1195–203.
154. Shen YM, Lee R, Frenkel E, Sarode R. IgA antiphospholipid antibodies are an independent risk factor for thromboses. Lupus 2008; 17: 996–1003.
155. Shiber S, Yair M. Catastrophic antiphospholipid syndrome: a case series. Isr Med Assoc J 2013; 15: 481–4.
156. Sidelmann JJ, Sjoland JA, Gram J, Bertelsen V, Mourits-Andersen T, Munster H, Munster AM, Jespersen J. Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. Scand J Clin Lab Invest 2007; 67: 270–9.
157. Singh K, Gaiha M, Shome DK, Gupta VK, Anuradha S. The association of antiphospholipid antibodies with ischaemic stroke and myocardial infarction in young and their correlation: a preliminary study. J Assoc Physicians India 2001; 49: 527–9.
158. Song KS, Kim HK. Prevalence of beta2-glycoprotein I antibody in patients with liver cirrhosis: relationship with beta2-glycoprotein I plasma levels and thrombosis. Clin Appl Thromb Hemost 2004; 10: 183–6.
159. Srikrishna A, Sitalakshmi S, Devi S, Damodar P, Varghese J, Suresh J, Mathew T. Antiphospholipid antibodies – our experience. Indian J Pathol Microbiol 2004; 47: 174–7.
160. Statkute L, Traynor A, Oyama Y, Yaung K, Verda L, Krosnjar N, Burt RK. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 2005; 106: 2700–9.
161. Staub HL, Norman GL, Crowther T, da Cunha VR, Polanczyk A, Bohn JM, Fernandes JG, Chahade WH, von Muhlen CA. Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr 2003; 61: 757–63.
162. Steiner S, Sadushi R, Bartok A, Hammer A, Quehenberger P, Mannhalter C, Koppensteiner R, Minar E, Kopp CW. Association of periprocedural neurological deficit in carotid stenting with increased anticardiolipin antibodies. Thromb Res 2009; 123: 827–31.
163. Stojanovich L. The catastrophic antiphospholipid syndrome in Serbia: diagnostic and management problems. Clin Rev Allergy Immunol 2009; 36: 98–103.
164. Stojanovich L, Kontic M, Djokovic A, Ilijevski N, Stanisavljevic N, Marisavljevic D. Pulmonary events in antiphospholipid syndrome: influence of antiphospholipid antibody type and levels. Scand J Rheumatol 2012; 41: 223–6.
165. Svenungsson E, Gustafsson J, Leonard D, Sandling J, Gunnarsson I, Nordmark G, Jonsen A, Bengtsson AA, Sturfelt G, Rantapaa-Dahlqvist S, Elvin K, Sundin U, Garnier S, Simard JF, Sigurdsson S, Padyukov L, Syvanen AC, Ronnblom L. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 834–40.
166. Swadzba J, Iwaniec T, Szczeklik A, Musial J. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost 2007; 5: 1883–9.
167. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29–36.
168. Tsutsumi A, Hayashi T, Chino Y, Mamura M, Goto D, Matsumoto I, Ito S, Sumida T. Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays. Mod Rheumatol 2006; 16: 158–64.
169. Turiel M, Sarzi-Puttini P, Peretti R, Rossi E, Atzeni F, Parsons W, Doria A. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke 2005; 36: 1490–4.
170. Vaidya S, Gugliuzza K, Daller JA. Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation 2004; 77: 1046–9.
171. van Cott EM, Laposata M, Hartnett ME. Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. Blood Coagul Fibrinolysis 2004; 15: 393–7.
172. Vaya A, Mira Y, Mateo J, Falco C, Villa P, Estelles A, Corella D, Fontcuberta J, Aznar J. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452–7.
173. Veres K, Lakos G, Kerenyi A, Szekanecz Z, Szegedi G, Shoenfeld Y, Soltesz P. Antiphospholipid antibodies in acute coronary syndrome. Lupus 2004; 13: 423–7.
174. Vikerfors A, Johansson AB, Gustafsson JT, Jonsen A, Leonard D, Zickert A, Nordmark G, Sturfelt G, Bengtsson A, Ronnblom L, Gunnarsson I, Elvin K, Svenungsson E. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford) 2013; 52: 501–9.
175. Viveros ME, Cabiedes J, Reyes E, Cabral AR. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies. Rev Invest Clin 2005; 57: 563–71.
176. von Landenberg P, Scholmerich J, von Kempis J, Lackner KJ. The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis. A retrospective study from a single center. Immunobiology 2003; 207: 65–71.
177. Voss A, Jacobsen S, Heegaard NH. Association of beta2-glycoprotein I IgG and IgM antibodies with thrombosis and thrombocytopenia. Lupus 2001; 10: 533–8.
178. Woo KS, Kim KE, Kim JM, Han JY, Chung WT, Kim KH. Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus. Korean J Lab Med 2010; 30: 38–44.
179. Wu H, Birmingham DJ, Rovin B, Hackshaw KV, Haddad N, Haden D, Yu CY, Hebert LA. D-dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol 2008; 3: 1628–36.
180. Wysokinska EM, Wysokinski WE, Brown RD, Karnicki K, Gosk-Beirska I, Grill D, McBane RD 2nd. Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis. Neurology 2008; 70: 627–33.
181. Yang YJ, Yun GW, Song IC, Baek SW, Lee KS, Ryu HW, Lee MW, Lee HJ, Yun HJ, Kim S, Jo DY. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med 2011; 26: 449–54.
182. Yonal I, Hindilerden F, Hancer VS, Artim-Esen B, Daglar A, Akadam B, Nalcaci M, Diz-Kucukkaya R. The impact of platelet membrane glycoprotein Ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome. Thromb Res 2012; 129: 486–91.
183. Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 2003; 12: 112–16.
184. Zamora-Ustaran A, Escarcega-Alarcon RO, Garcia-Carrasco M, Faugier E, Mendieta-Zeron S, Mendoza-Pinto C, Montiel-Jarquin A, Munoz-Guarneros M, Lopez-Colombo A, Cervera R. Antiphospholipid syndrome in Mexican children. Isr Med Assoc J 2012; 14: 286–9.
185. Zigon P, Cucnik S, Ambrozic A, Kveder T, Semrl SS, Rozman B, Bozic B. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol 2013; 2013: 724592.
186. Zoghlami-Rintelen C, Vormittag R, Sailer T, Lehr S, Quehenberger P, Rumpold H, Male C, Pabinger I. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160–5.
187. Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol 2012; 87(Suppl. 1): S75–81.
188. Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol 2009; 83: 1–16.
189. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–42.
190. Pelkmans L, de Laat B. Antibodies against domain I of beta2-glycoprotein I: the one and only? Lupus 2012; 21: 769–72.
191. Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E, Denas G, Padayattil Jose S. Antiphospholipid syndrome: antibodies to domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015; 13: 782–7.
192. Banzato A, Pozzi N, Frasson R, De Filippis V, Ruffatti A, Bison E, Padayattil SJ, Denas G, Pengo V. Antibodies to domain I of beta(2)glycoprotein I are in close relation to patient risk categories in antiphospholipid syndrome (APS). Thromb Res 2011; 128: 583–6.
193. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916–24.
194. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40–Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540–5.
195. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep 2007; 9: 212–18.